METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to fight tough head and neck cancers
Disease control OngoingThis study is testing a new combination of three drugs—olaparib, pembrolizumab, and carboplatin—as the first treatment for people with advanced head and neck cancer that has returned or spread. The goal is to see if this three-drug mix can shrink tumors better than standard treat…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug duo aims to boost immune System's fight against tough cancer
Disease control OngoingThis study is testing if adding a drug called ramucirumab to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has returned or spread. The goal is to see if the combination helps shrink tumors and control…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New combo therapy tested for Tough-to-Treat head and neck cancers
Disease control OngoingThis study is testing a two-drug combination for adults with advanced head and neck cancer that has spread or returned and has gotten worse despite prior immunotherapy. The goal is to see if adding a chemotherapy drug (nab-paclitaxel) to an immunotherapy drug (nivolumab) can shri…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug cocktail aims to stall aggressive head and neck cancers
Disease control OngoingThis study tested whether adding the drug sorafenib to two standard chemotherapy drugs (carboplatin and paclitaxel) could better control advanced head and neck cancer that has returned or spread. It involved 48 patients with this difficult-to-treat cancer. The main goal was to se…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Scientists test Immune-Boosting combo against tough head & neck cancers
Disease control OngoingThis study is testing a combination of two drugs, cetuximab and interleukin-12, for patients with advanced head and neck cancer that has returned, spread, or cannot be removed by surgery. The first goal is to find a safe dose of interleukin-12 to use with cetuximab. The second go…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Scientists test new drug duo to fight tough cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Could daily fasting boost cancer treatment?
Disease control TerminatedThis study aimed to see if time-restricted eating (limiting food to a 10-hour daily window) could improve outcomes for people with advanced head & neck or kidney cancer receiving immunotherapy. Researchers wanted to learn if this eating pattern changes gut bacteria and the body's…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug combo aims to tame tough head and neck cancers
Disease control OngoingThis study is testing whether combining an immunotherapy drug (cemiplimab) with two low-dose chemotherapy drugs works better for treating head and neck cancer that has returned or spread. It will involve about 46 patients whose cancer has come back or spread and who haven't had o…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Two-Drug attack on tough head and neck cancers
Disease control OngoingThis study is testing if adding a new drug called ipatasertib to a standard immunotherapy (pembrolizumab) works better for controlling advanced head and neck cancer that has returned or spread. It will involve about 52 adults who have not yet received treatment for their advanced…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Radiation boost tested to help immune system fight advanced head and neck cancer
Disease control OngoingThis study is for adults whose head and neck cancer has spread to a few other places in the body. It tests if adding a targeted course of radiation therapy to standard immunotherapy helps patients live longer than immunotherapy alone. About 290 participants will be randomly assig…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New hope for tough head & neck cancers that resist First-Line treatment
Disease control OngoingThis study is for people with advanced head and neck cancer that has returned or spread after their first immunotherapy treatment stopped working. It compares three different drug combinations to see which one is better at controlling the cancer and helping patients live longer. …
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC